“There was about a 32.5% survival advantage for patients with that triple therapy,” says Michael S. Cookson, MD, MMHC.
In this video, Michael S. Cookson, MD, MMHC, discusses the background and notable findings of the study, “Darolutamide in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer: overall survival and other outcomes of the phase 3 ARASENS trial,” which will be presented at the 2022 South Central Section of the AUA Annual Meeting in Coronado, California. professor and chair of urology at the University of Oklahoma Health Sciences Center in Oklahoma City, is co-editor in chief of Urology Times.®
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.